Sequencing information has identified mutations in other genes of interest that might be clinically relevant in breast cancer such as KRAS, NF2, SKT11, APC, and AKT2. A precise test of these breast cancer-associated genes can guide examination and preventive treatment based on the objective risk measurement such as the increased frequency of prophylactic surgery, chemoprevention, and mammography (Cui et al., 2014). This evidence concerns the gene NF2 and breast carcinoma.